drugset / Trial / NCT01964560

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

NCT01964560

Phase 3 Completed 540 enrolled UCB BIOSCIENCES, Inc. UCB Biopharma SRL · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of lacosamide (LCM) in pediatric subjects.

Timeline

Start
2014-08-13
Primary completion
2022-04-13
Completion
2022-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacosamide Other / unclassified 1 mg/kg Oral
Subject Lacosamide Other / unclassified 6 mg/kg Oral
Subject Lacosamide Other / unclassified 50 mg Oral
Subject Lacosamide Other / unclassified 300 mg Oral

Indications